3rd Quarter - Report
DLA PIPER LLP (US) for BIOHAVEN PHARMACEUTICALS, INC.
Firm
Income
$60,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARINA LYNCH | — |
| ALEX PINSON | — |
| VINCENT SARUBBI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.